Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics has a late-stage obesity drug candidate, VK2735, with catalysts ahead: maintenance-dose data in Q3 and a phase 3 launch for the oral version in Q4. The stock has fallen from a February 2024 high above $94 to about $27, but Wall Street’s average 12-month target is still above $92, implying substantial upside. The article is constructive on the company’s pipeline and potential commercialization, though it remains speculative until late-stage data and regulatory progress materialize.

Analysis

VKTX is starting to trade less like a discovery-stage biotech and more like a binary options market on obesity commercialization. The important second-order effect is not just whether the drug works, but whether the company can force a re-rating before phase 3 de-risks fully; in obesity, valuation often moves on duration of efficacy, tolerability, and formulation convenience long before revenue exists. That means near-term price action can remain dominated by catalyst timing rather than fundamentals, which creates opportunity for event-driven positioning but also makes straight equity longs vulnerable to “good-but-not-good-enough” readouts.

The clearest competitive angle is formulation optionality. If an oral-to-injectable treatment path is validated, VKTX could capture patients who want lower-friction initiation and then higher-potency maintenance, which expands addressable persistence versus single-format competitors. The flip side is that large incumbents can neutralize this by bundling access, payer rebates, and manufacturing scale; so the real threat to VKTX is not another molecule, but a reimbursement war that compresses realized net price and slows uptake even if clinical data are strong.

Consensus appears to be underpricing how fragile the stock is to trial design nuances. A maintenance study or phase 3 launch headline can support a sharp rally, but any signal of dose-limiting GI tolerability, weaker maintenance of weight loss, or slower oral absorption would likely knock 20-30% off the equity quickly because the company lacks commercial earnings to cushion disappointment. Conversely, if the next updates merely confirm continuity rather than step-function superiority, the upside may be capped by the market’s tendency to discount a long regulatory timeline and the eventual need for massive commercial spend.

Key Decisions for Investors

• Trade the catalyst: buy VKTX into the next clinical readout window, but define risk tightly with a 15-20% stop; upside into a clean maintenance-data surprise could be 30-50% on a short squeeze, while downside on any tolerability miss is likely abrupt.
• Use options instead of common stock: buy 3-6 month VKTX call spreads to express upside to the phase 3/oral-launch sequence with capped premium risk; this is preferable given the stock’s tendency to gap on data.
• Relative-value pair: long VKTX / short NVO or LLY only as a temporary event trade, not a structural bet; the goal is to capture multiple expansion in the smaller name if obesity sentiment re-accelerates, while avoiding outright sector beta.
• For risk-off accounts, wait for post-data confirmation before establishing a core position; if the stock rallies on headline and then holds gains for 2-3 weeks, that is the cleaner entry because it implies institutions are underwriting the catalyst rather than just trading it.
• If the next update is merely confirmatory, consider fading strength with a short-term covered-call overlay on VKTX to monetize elevated implied volatility while limiting downside participation.